Antibody Information

General Information of This Antibody
Antibody ID
ANI0ABINN
Antibody Name
MAB100
Synonyms
UCHT1
   Click to Show/Hide
Antibody Type
Monoclonal antibody (mAb)
Antibody Subtype
Chimeric IgG1-kappa
Antigen Name
Epidermal growth factor receptor (EGFR)
  Antigen Info 
Click to Show/Hide the Sequence Information of This Antibody
Heavy Chain Sequence
DILLTQSPVILSVSPGERVSFSCRASQSIGTNIHWYQQRTNGSPRLLIKYASESISGIPS
RFSGSGSGTDFTLSINSVESEDIADYYCQQNNNWPTTFGAGTKLELKRTVAAPSVFIFPP
SDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLT
LSKADYEKHKVYACEVTHQGLSSPVTKSFNRGE
    Click to Show/Hide
Light Chain Sequence
QVQLKQSGPGLVQPSQSLSITCTVSGFSLTNYGVHWVRQSPGKGLEWLGVIWSGGNTDYN
TPFTSRLSINKDNSKSQVFFKMNSLQSNDTAIYYCARALTYADYEFAYWGQGTLVTVSA
    Click to Show/Hide
Each Antibody-drug Conjugate Related to This Antibody
Full Information of The Activity Data of The ADC(s) Related to This Antibody
AVID-100 [Phase 2]
 ADC Info 
Identified from the Human Clinical Data
Click To Hide/Show 1 Activity Data Related to This Level
Experiment 1 Reporting the Activity Date of This ADC [1]
Patients Enrolled
Patients with advanced or metastatic epithelial malignancies.
Administration Dosage
20, 40, 80, 120, 180, and 220 mg/m2 every 3 weeks.
Related Clinical Trial
NCT Number NCT03094169  Clinical Status Phase 1/2
Clinical Description
Phase 1a/2a dose escalation trial to determine safety, tolerance, MTD, and preliminary antineoplastic activity of AVID100, in patients with advanced or metastatic solid tumors of epithelial origin.
References
Ref 1 First-in-human study of the B7-H4 antibody-drug conjugate (ADC) AZD8205 in patients with advanced/metastatic solid tumors. J Clin Oncol. 2022 40:16_suppl, TPS3153-TPS3153.

If you find any error in data or bug in web service, please kindly report it to Dr. Shen et al.